ClinicalTrials.gg
Drug

Ensartinib clinical trials

Also written X-396.

studies test it
33
open now
13
in phase 3
2
first study started
2012

How each study uses ensartinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ensartinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Dec 2024 · ENSACOVE · NDA 218171 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ensartinib
24
X 396
3
X396
3
X-396 capsule
3

Development codes

X-396
13

Studies by the year they started

33 studies that test it; most in 2018 (6)

Studies that test ensartinib, by start year
YearStudies
20121
20161
20174
20186
20193
20212
20226
20242
20256
20262

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
24
Phase 3
2
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 21

Betta Pharmaceuticals Co., Ltd. (9) · National Cancer Institute (NCI) (3) · Xcovery Holdings, Inc. (3) · Sun Yat-sen University (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Peking University Cancer Hospital & Institute (2) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1)

Often tested with

Tested in the same studies.

Crizotinib (3) · Larotrectinib (2) · Erdafitinib (1) · Ivosidenib (1) · Olaparib (1) · Palbociclib (1) · LY3023414 (1) · Selpercatinib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test ensartinib.

Studies

Open first, then newest update. How each study uses ensartinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 33

See all 33 studies that test ensartinib →

Given beside what is tested · 1 — ensartinib is usual care or a partner of the new treatment

Codes

What other systems call ensartinib · ClinicalTrials.gg INT001018

  • MeSH (NLM) C000629294ensartinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) SMA5ZS5B22ENSARTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27896019ensartinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C102754EnsartinibOne source FDA
  • DrugBank DB14860One source Wikidata

Also registered as ensartinib hydrochloride (UNII C2FR6VT1BQ).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.